Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis

Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF